Nanoengineered drug delivery systems for enhancing antibiotic therapy

Journal of Pharmaceutical Sciences

Volumn 104, Issue 3, 2015, Pages 872-905

  Kalhapure, Rahul S ^a   Suleman, Nadia ^a   Mocktar, Chunderika ^a   Seedat, Nasreen ^a   Govender, Thirumala ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Antibiotic resistance; Controlled release; Infectious diseases; Nanoantibiotics; Nanodrug delivery systems; Nanotechnology; Polymeric drug carrier; Polymeric drug delivery systems; Targeted drug delivery

Indexed keywords

AMIKACIN; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFALEXIN; CEFALOTIN; CEFRADINE; CEFTEZOLE; CIPROFLOXACIN; DIHYDROSTREPTOMYCIN; FILIPIN; GENTAMICIN; LIPID; LIPOSOME; MEROPENEM; MOLECULAR SCAFFOLD; NANOCARRIER; NANOFIBER; NANOPARTICLE; NETILMICIN; PENICILLIN G; PHOSPHATIDYLCHOLINE; POLYMER; RIFAMPICIN; SOLID LIPID NANOPARTICLE; SULFADIAZINE SILVER; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LIPID VESICLE; MICELLE; MINIMUM INHIBITORY CONCENTRATION; NANOEMULSION; NANOENGINEERING; NANOTECHNOLOGY; NONHUMAN; PHOSPHOLIPID BILAYER; PHYSICAL CHEMISTRY; REVIEW; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; MEDICINAL CHEMISTRY; NANOMEDICINE; PHARMACEUTICS; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG RESISTANCE, BACTERIAL; HUMANS; NANOMEDICINE; NANOPARTICLES; POLYMERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84922829810     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24298     Document Type: Review

References (322)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY. 2013. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. The Lancet 380 (9859) : 2095-2128.
2. Winters C, Gelband H. 2011. The global antibiotic resistance partnership. S Afr Med J 101 (8) : 556-557.
3. Huh AJ, Kwon YJ. 2011. Nanoantibiotics: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 156 (2) : 128-145.
4. Ogoina D, Onyemelukwe GC. 2009. The role of infections in the emergence of non-communicable diseases (NCDs) : Compelling needs for novel strategies in the developing world. J Infect Public Health 2 (1) : 14-29.
5. Cars O, Hedin A, Heddini A. 2011. The global need for effective antibiotics-Moving towards concerted action. Drug Resist Updates 14 (2) : 68-69.
6. Sharma A, Kumar Arya D, Dua M, Chhatwal GS, Johri AK. 2012. Nano-Technology for targeted drug delivery to combat antibiotic resistance. Expert Opin Drug Deliv 9 (11) : 1325-1332.
7. Cohen ML. 2000. Changing patterns of infectious diseases. Nature 406: 762-767.
8. Gold HS, Moellering RC. 1996. Antimicrobial-drug resistance. N Engl J Med 335: 1445-1453.
9. Perichon B, Courvalin P. 2009. VanA-Type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53 (11) : 4580-4587.
10. Walsh CT. 2005. Antimicrobials. Curr Opin Microbiol 8: 495-497.
11. Seil JT, Webster TJ. 2012. Antimicrobial applications of nanotechnology: Methods and literature. Int J Nanomed 7: 2767.
12. News Release. WHO's prst global report on antibiotic resistance reveals serious, worldwide threat to public health Accessed June 12, 2014, at: Http://www.who.int/mediacentre/news/releases/2014/amr-report/en/.
13. Taubes G. 2008. The bacteria pght back. Science 321: 356-361.
14. Sondi I, Salopek-Sondi B. 2004. Silver nanoparticles as antimicrobial agent: A case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 275 (1) : 177-182.
15. Accessed October 23, 2013, at: Www.apua.org.
16. Parhi P, Mohanty C, Sahoo SK. 2012. Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy. Drug Discov Today 17: 1044-1052.
17. Tekade RK, Kumar PV, Jain NK. 2009. Dendrimers in oncology: An expanding horizon. Chem Rev 109: 49-87.
18. Kawasaki ES, Player A. 2005. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomed Nanotech Biol Med 1 (2) : 101-109.
19. Park JW. 2002. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4: 95-99.
20. Gerson T, Makarov E, Senanayake TH, Gorantla S, Poluektova LY, Vinogradov SV. 2014. Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain. Nanomed Nanotech Biol Med 10 (1) : 177-185.
21. Gupta U, Jain NK. 2010. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev 62 (4-5) : 478-490.
22. Branham ML, Moyo T, Govender T. 2012. Preparation and solidstate characterization of ball milled saquinavir mesylate for solubility enhancement. Eur J Pharm Biopharm 80 (1) : 194-202.
23. Moretton MA, et al., Novel nelpnavir mesylate loaded dtocopheryl polyethylene glycol 1000 succinate micelles for enhanced pediatric anti HIV therapy: In vitro characterization and in vivo evaluation, Colloids Surf. B: Biointerfaces (2014), http://dx.doi.org/10.1016/j.colsurfb.2014.09.031.
24. Govender T, Ojewole E, Naidoo P, Mackraj I. 2008. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv 15 (8) : 493-501.
25. Shah PP, Desai PR, Singh M. 2012. Effect of oleic acid modiped polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Release 158: 336-345.
26. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG. 2010. A novel nanoparticle drug delivery system: The antiinammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 18: 1606-1614.
27. Du Toit LC, Govender T, Carmichael T, Kumar P, Choonara YE, Pillay V. 2013. Design of an anti-inammatory composite nanosystem and evaluation of its potential for ocular drug delivery. J Pharm Sci 102 (8) : 2780-2805.
28. Kalhapure RS, Akamanchi KG. 2012. Oleic acid based heterolipid synthesis, characterization and application in self-microemulsifying drug delivery system. Int J Pharm 425: 9-18.
29. Bonner JC, Card JW, Zeldin DC. 2009. Nanoparticle-mediated drug delivery and pulmonary hypertension. Hypertension 53 (751-753) : 751.
30. Shetty RC. 2006. Benepts of nanotechnology in cardiovascular surgery-A review of potential applications. US Cardiol 3: 1-3.
31. Zhang D, Pornpattananangkul D, Hu CM, Huang CM. 2010. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 17: 585-594.
32. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. 2008. Nanoparticles in medicine: The therapeutic applications and developments. Clin Pharmacol Ther 83: 761-769.
33. Sosnik A, Carcaboso A M, Glisoni RJ, Moretton MA, Chiappetta DA. 2010. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 62 (4-5) : 547-559.
34. Mansour HM, Rhee YS, Wu X. 2009. Nanomedicine in pulmonary delivery. J Nanomed 4: 299-319.
35. Pelgrift RY, Friedman AJ. 2013. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 65 (13-14) : 1803-1815.
36. Blecher K, Nasir A, Friedman A. 2011. The growing role of nanotechnology in combating infectious disease. Virulence 2 (5) : 395-401.
37. Couvreur P. 2013. Nanoparticles in drug delivery: Past, present and future. Adv Drug Deliv Rev 65 (1) : 21-23.
38. Allen T, Cullis P. 2013. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 65 (1) : 36-48.
39. du Plessis J, Ramachandran C,Weiner N,Muller DG. 1996. The inuence of lipid composition and lamellarity of liposomes on the physical stability of liposomes upon storage. Int J Pharm 127 (2) : 273-278.
40. Vemuri S, Rhodes CT. 1995. Preparation and characterization of liposomes as therapeutic delivery systems: A review. Pharm Acta Helv 70 (2) : 95-111.
41. Bangham A. 1978. Properties and uses of lipid vesicles: An overview. Ann N Y Acad Sci 308 (1) : 2-7.
42. Szoka F, Papahadjopoulos D. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reversephase evaporation. PNAS 75 (9) : 4194-4198.
43. Deamer DW. 1978. Preparation and properties of ether-injection liposomes. Ann N Y Acad Sci 308 (1) : 250-258.
44. Stano P, Bufali S, Pisano C, Bucci F, Barbarino M, Santaniello M, Carminati P, Luisi PL. 2004. Novel camptothecin analogue (gimatecan) -containing liposomes prepared by the ethanol injection method. J Liposome Res 14 (1-2) : 87-109.
45. Zumbuehl O, Weder HG. 1981. Liposomes of controllable size in the range of 40 to 180 nm by depned dialysis of lipid/detergent mixed micelles. Bichim Biophys Acta 640 (1) : 252-262.
46. Otake K, Shimomura T, Goto T, Imura T, Furuya T, Yoda S, Takebayashi Y, Sakai H, Abe M. 2006. Preparation of liposomes using an improved supercritical reverse phase evaporation method. Langmuir 22 (6) : 2543-2550.
47. Skalko-Basnet N, Pavelic Z, Becirevic-Lacan M. 2000. Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev Ind Pharm 26 (12) : 1279-1284.
48. Li C, Deng Y. 2004. A novel method for the preparation of liposomes: Freeze drying of monophase solutions. J Pharm Sci 93 (6) : 1403-1414.
49. Hope M, Bally M, Webb G, Cullis P. 1985. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812 (1) : 55-65.
50. Saunders L, Perrin J, Gammack D. 1962. Ultrasonic irradiation of some phospholipid sols. J Pharm Pharmacol 14 (1) : 567-572.
51. Jahn A, Vreeland WN, Gaitan M, Locascio LE. 2004. Controlled vesicle self-Assembly in microuidic channels with hydrodynamic focusing. J Am Chem Soc 126 (9) : 2674-2675.
52. Pradhan P, Guan J, Lu D, Wang PG, Lee LJ, Lee RJ. 2008. A facile microuidic method for production of liposomes. Anticancer Res 28 (2A) : 943-947.
53. Vemuri S, Yu C-D,Wangsatorntanakun V, Roosdorp N. 1990. Largescale production of liposomes by a microuidizer. Drug Dev Ind Pharm 16 (15) : 2243-2256.
54. Wagner A, Platzgummer M, Kreismayr G, Quendler H, Stiegler G, Ferko B, Vecera G, Vorauer-Uhl K, Katinger H. 2006. GMP production of liposomes-A new industrial approach. J Liposome Res 16 (3) : 311-319.
55. Charcosset C. 2006. Membrane processes in biotechnology: An overview. Biotech Adv 24 (5) : 482-492.
56. Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H. 2010. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res 20 (3) : 228-243.
57. Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H. 2011. Liposome preparation using a hollow pber membrane contactor-Application to spironolactone encapsulation. Int J Pharm 415 (1) : 53-61.
58. Yang D, Pornpattananangkul D, Nakatsuji T, Chan M, Carson D, Huang C-M, Zhang L. 2009. The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials 30 (30) : 6035-6040.
59. Castro GA, Ferreira LA. 2008. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin Drug Deliv 5 (6) : 665-679.
60. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4 (2) : 145-160.
61. Lasic DD. 1998. Novel applications of liposomes. Trends Biotechnol 16 (7) : 307-321.
62. Schiffelers R, Storm G, Bakker-Woudenberg I. 2001. Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 48 (3) : 333-344.
63. Sessa G, Weissmann G. 1968. Effects of four components of the polyene antibiotic, plipin, on phospholipid spherules (liposomes) and erythrocytes. J Biol Chem 243 (16) : 4364-4371.
64. Gregoriadis G. 1973. Drug entrapment in liposomes. FEBS Lett 36 (3) : 292-296.
65. Bonventre P, Gregoriandis G. 1978. Killing of intraphagocytic Staphylococcus aureus by dihydrostreptomycin entrapped within liposomes. Antimicrob Agents Chemother 13 (6) : 1049-1051.
66. Kimura T, Yoshikawa M, Yasuhara M, Sezaki H. 1980. The use of liposomes as a model for drug absorption: Beta-lactam antibiotics. J Pharm Pharmacol 32 (6) : 394-398.
67. Desiderio JV, Campbell SG. 1983. Intraphagocytic killing of Salmonella typhimurium by liposome-encapsulated cephalothin. J Infect Dis 148 (3) : 563-570.
68. Ito M, Ishida E, Tanabe F, Mori N, Shigeta S. 1986. Inhibitory effect of liposome-encapsulated penicillin G on growth of Listeria monocytogenes in mouse macrophages. Tohoku J Exp Med 150 (3) : 281-286.
69. Price CI, Horton JW, Baxter CR. 1990. Topical liposomal delivery of antibiotics in soft tissue infection. J Surg Res 49 (2) : 174-178.
70. Onyeji C, Nightingale C, Marangos M. 1994. Enhanced killing of methicillin-resistant Staphylococcus aureus in human macrophages by liposome-entrapped vancomycin and teicoplanin. Infection 22 (5) : 338-342.
71. Omri A, Ravaoarinoro M. 1996. Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria. Int J Antimicrob Agents 7 (1) : 9-14.
72. Schumacher I, Margalit R. 1997. Liposome-encapsulated ampicillin: Physicochemical and antibacterial properties. J Pharm Sci 86 (5) : 635-641.
73. Cabanes A, Reig F, Garcia-Anton J, Arboix M. 1998. Evaluation of free and liposome-encapsulated gentamycin for intramuscular sustained release in rabbits. Res Vet Sci 64 (3) : 213-217.
74. Leitzke S, Bucke W, Borner K, Muller R, Hahn H, Ehlers S. 1998. Rationale for and efpcacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother 42 (2) : 459-461.
75. Furneri PM, Fresta M, Puglisi G, Tempera G. 2000. Ooxacinloaded liposomes: In vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother 44 (9) : 2458-2464.
76. Kim H-J, Jones MN. 2004. The delivery of benzyl penicillin to Staphylococcus aureus bioplms by use of liposomes. J Liposome Res 14 (3-4) : 123-139.
77. Kadry AA, Al-Suwayeh SA, Abd-Allah AR, Bayomi MA. 2004. Treatment of experimental osteomyelitis by liposomal antibiotics. J Antimicrob Chemother 54 (6) : 1103-1108.
78. Drulis-Kawa Z, Gubernator J, Dorotkiewicz-Jach A, Doroszkiewicz W, Kozubek A. 2006. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. Int J Pharm 315 (1) : 59-66.
79. Rukholm G, Mugabe C, Azghani AO, Omri A. 2006. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: A time-kill study. Int J Antimicrob Agents 27 (3) : 247-252.
80. Pasquardini L, Lunelli L, Vanzetti L, Anderle M, Pederzolli C. 2008. Immobilization of cationic rifampicin-loaded liposomes on polystyrene for drug-delivery applications. Colloids Surf B 62 (2) : 265-272.
81. Muppidi K, Wang J, Betageri G, Pumerantz AS. 2011. PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob Agents Chemother 55 (10) : 4537-4542.
82. Pornpattananangkul D, Zhang L, Olson S, Aryal S, Obonyo M, Vecchio K, Huang C-M, Zhang L. 2011. Bacterial toxin-Triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Am Chem Soc 133 (11) : 4132-4139.
83. Zhao W, Wu W, Xu X. 2007. Oral vaccination with liposomeencapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice. Vaccine 25 (44) : 7664-7673.
84. Fielding RM. 1991. Liposomal drug delivery: Advantages and limitations from a clinical pharmacokinetics and therapeutic perspective. Clin Pharmacokinet 21: 155-164.
85. Immordino ML. 2006. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1 (3) : 297-315.
86. Trafny EA, Stepi nska M, Antos M, Grzybowski J. 1995. Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I. Antimicrob Agents Chemother 39 (12) : 2645-2649.
87. Wang B, Zhang L, Bae SC, Granick S. 2008. Nanoparticleinduced surface reconstruction of phospholipid membranes. PNAS 105 (47) : 18171-18175.
88. Woodle MC. 1998. Controlling liposome blood clearance by surfacegrafted polymers. Adv Drug Deliv Rev 32 (1) : 139-152.
89. Bhakdi S, Tranum-Jensen J. 1991. Alpha-Toxin of Staphylococcus aureus. Microbiol Rev 55 (4) : 733-751.
90. Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, Gouaux JE. 1996. Structure of staphylococcal hemolysin, a heptameric transmembrane pore. Science 274 (5294) : 1859-1865.
91. Meesters C, Brack A, Hellmann N, Decker H. 2009. Structural characterization of the hemolysin monomer from Staphylococcus aureus. Proteins 75 (1) : 118-126.
92. Lockman P, Mumper R, Khan M, Allen D. 2002. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28 (1) : 1-13.
93. Pinto-Alphandary H, Andremont A, Couvreur P. 2000. Targeted delivery of antibiotics using liposomes and nanoparticles: Research and applications. Int J Antimicrob Agents 13 (3) : 155-168.
94. Misra R, Sahoo SK. 2012. Antibacterial activity of doxycyclineloaded nanoparticles. Methods Enzymol 509: 61-85.
95. Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Illum L, Davis SS. 2000. Depning the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm 199 (1) : 95-110.
96. Lai P, Daear W, Lobenberg R, Prenner EJ. 2014. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (D,L-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B 118: 154-163.
97. Bakker-Woudenberg IAJM, Storm G, Woodle MC. 1994. Liposomes in the treatment of infections. J Drug Target 2 (5) : 363-371.
98. Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Preat V. 2014. pH-sensitive nanoparticles for colonic delivery of curcumin in inammatory bowel disease. Int J Pharm 473 (1-2) : 203-212.
99. Verderio P, Pandolp L, Mazzucchelli S, Marinozzi MR, Vanna R, Gramatica F, Corsi F, Colombo M, Morasso C, Prosperi D. 2014. Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells. Mol Pharm 11 (8) : 2864-2875.
100. Shah U, Joshi G, Sawant K. 2014. Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. Mater Sci Eng C 35 (0) : 153-163.
101. Yoo D, Guk K, Kim H, Khang G, Wu D, Lee D. 2013. Antioxidant polymeric nanoparticles as novel therapeutics for airway inammatory diseases. Int J Pharm 450 (1-2) : 87-94.
102. Vijayan V, Reddy KR, Sakthivel S, Swetha C. 2013. Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: In vitro and in vivo studies. Colloids Surf B 111 (0) : 150-155.
103. Zhang T, Sturgis TF, Youan B-BC. 2011. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm 79 (3) : 526-536.
104. Zhang L, Pornpattananangkul D, Hu C-M, Huang C-M. 2010. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 17 (6) : 585-594.
105. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. 2001. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70 (1) : 1-20.
106. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. 1997. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63: 125-132.
107. Doustgani A, Farahani EV, Imani M, Doulabi AH. 2012. Dexamethasone sodium phosphate release from chitosan nanoparticles prepared by ionic gelation method. J Colloid Sci Biotech 1 (1) : 42-50.
108. Takebe G, Takagi T, Suzuki M, Hiramatsu M. 2011. Preparation of polymeric nanoparticles of cyclosporin A using infrared pulsed laser. Int J Pharm 414 (1-2) : 244-250.
109. Fattal E, Youssef M, Couvreur P, Andremont A. 1989. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother 33 (9) : 1540-1543.
110. Couvreur P, Fattal E, Alphandary H, Puisieux F, Andremont A. 1992. Intracellular targeting of antibiotics by means of biodegradable nanoparticles. J Control Release 19 (1) : 259-267.
111. Fresta M, Puglisi G, Giammona G, Cavallaro G, Micali N, Furneri PM. 1995. Peoxacine mesilate-And ooxacin-loaded polyethylcyanoacrylate nanoparticles: Characterization of the colloidal drug carrier formulation. J Pharm Sci 84 (7) : 895-902.
112. Page-Clisson M-E, Pinto-Alphandary H, Ourevitch M, Andremont A, Couvreur P. 1998. Development of ciprooxacin-loaded nanoparticles: Physicochemical study of the drug carrier. J Control Release 56 (1) : 23-32.
113. Umamaheshwari R, Jain N. 2003. Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target 11 (7) : 415-424.
114. Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A. 2004. Factorial design, physicochemical characterisation and activity of ciprooxacin-PLGA nanoparticles. Int J Pharm 275 (1-2) : 171-187.
115. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. 2006. Evaluation of ciprooxacin-loaded EudragitR-RS100 or RL100/PLGA nanoparticles. Int J Pharm 314 (1) : 72-82.
116. Dillen K, Bridts C, Van der Veken P, Cos P, Vandervoort J, Augustyns K, Stevens W, Ludwig A. 2008. Adhesion of PLGA or EudragitR/PLGA nanoparticles to Staphylococcus and Pseudomonas. Int J Pharm 349 (1-2) : 234-240.
117. Turos E, Reddy GSK, Greenhalgh K, Ramaraju P, Abeylath SC, Jang S, Dickey S, LimDV. 2007. Penicillin-bound polyacrylate nanoparticles: Restoring the activity of lactam antibiotics against MRSA. Bioorg Med Chem Lett 17 (12) : 3468-3472.
118. Turos E, Shim J-Y, Wang Y, Greenhalgh K, Reddy G, Dickey S, Lim DV. 2007. Antibiotic-conjugated polyacrylate nanoparticles: New opportunities for development of anti-MRSA agents. Bioorg Med Chem Lett 17 (1) : 53-56.
119. Jeong Y-I, Na H-S, Seo D-H, Kim D-G, Lee H-C, Jang M-K, Na S-K, Roh S-H, Kim S-I, Nah J-W. 2008. Ciprooxacin-encapsulated poly (DLlactide-co-glycolide) nanoparticles and its antibacterial activity. Int J Pharm 352 (1-2) : 317-323.
120. Misra R, Acharya S, Dilnawaz F, Sahoo SK. 2009. Sustained antibacterial activity of doxycycline-loaded poly (D, L-lactideco-glycolide) and poly (g-caprolactone) nanoparticles. Nanomedicine (Lond) 4 (5) : 519-530.
121. Mohammadi G, Valizadeh H, Barzegar-Jalali M, Lotppour F, Adibkia K, Milani M, Azhdarzadeh M, Kiafar F, Nokhodchi A. 2010. Development of azithromycin-PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf B 80 (1) : 34-39.
122. Cheow WS, Hadinoto K. 2010. Enhancing encapsulation efpciency of highly water-soluble antibiotic in poly (lactic-co-glycolic acid) nanoparticles: Modipcations of standard nanoparticle preparation methods. Colloids Surf A 370 (1-3) : 79-86.
123. Chakraborty SP, Sahu SK, Mahapatra SK, Santra S, Bal M, Roy S, Pramanik P. 2010. Nanoconjugated vancomycin: New opportunities for the development of anti-VRSA agents. Nanotechnology 21 (10) : 105103.
124. Toti US, Guru BR, Hali M, McPharlin CM, Wykes SM, Panyam J, Whittum-Hudson JA. 2011. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 32 (27) : 6606-6613.
125. Pichavant L, Bourget C, Durrieu M-C, Heroguez V. 2011. Synthesis of pH-sensitive particles for local delivery of an antibiotic via dispersion ROMP. Macromolecules 44 (20) : 7879-7887.
126. Maya S, Indulekha S, Sukhithasri V, Smitha KT, Nair SV, Jayakumar R, Biswas R. 2012. Efpcacy of tetracycline encapsulated O-carboxymethyl chitosan nanoparticles against intracellular infections of Staphylococcus aureus. Int J Biol Macromol 51 (4) : 392-399.
127. Ungaro F, d'Angelo I, Coletta C, d'Emmanuele di Villa Bianca R, Sorrentino R, Perfetto B, Tufano MA, Miro A, La Rotonda MI, Quaglia F. 2012. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efpciency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 157 (1) : 149-159.
128. Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC. 2012. Surface charge-switching polymeric nanoparticles for bacterial cell wall-Targeted delivery of antibiotics. ACS Nano 6 (5) : 4279-4287.
129. Lin YH, Tsai SC, Lai CH, Lee CH, He ZS, Tseng GC. 2013. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials 34 (18) : 4466-4479.
130. Zakeri-Milani P, Loveymi BD, Jelvehgari M, Valizadeh H. 2013. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B 103: 174-181.
131. Glowka E, Wosicka-FraPckowiak H, Hyla K, Stefanowska J, Jastrz P ebska K, Klapiszewski L, Jesionowski T, Cal K. 2014. Polymeric nanoparticles-embedded organogel for roxithromycin delivery to hair follicles. Eur J Pharm Biopharm 88 (1) : 75-84.
132. Kalhapure RS, Akamanchi KG, Mocktar C, Govender T. 2014. Synthesis and antibacterial activity of silver nanoparticles capped with a carboxylic acid terminated generation 1 oleodendrimer. Chem Lett 43: 1110-1112.
133. Ashfaq M, Khan S, Verma N. 2014. Synthesis of PVA-CAP-based biomaterial in situ dispersed with Cu nanoparticles and carbon micronanopbers for antibiotic drug delivery applications. Biochem Eng J 90 (0) : 79-89.
134. Moazzen E, Ebrahimzadeh H, Amini MM, Sadeghi O. 2013. A novel biocompatible drug carrier for oral delivery and controlled release of antibiotic drug: Loading and release of clarithromycin as an antibiotic drug model. J Sol-Gel Sci Technol 66 (2) : 345-351.
135. Kalhapure RS, Mocktar C, Sikwal DR, Sonawane SJ, Kathiravan MK, Skelton A, Govender T. 2014. Ion pairing with linoleic acid simultaneously enhances encapsulation efpciency and antibacterial activity of vancomycin in solid lipid nanoparticles. Colloids Surf B 117: 303-311.
136. Prombutara P, Kulwatthanasal Y, Supaka N, Sramala I, Chareonpornwattana S. 2012. Production of nisin-loaded solid lipid nanoparticles for sustained antimicrobial activity. Food Control 24 (1-2) : 184-190.
137. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. 1999. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Control Release 57 (2) : 171-185.
138. Rabea EI, Badawy MET, Stevens CV, Smagghe G, Steurbaut W. 2003. Chitosan as antimicrobial agent: Applications and mode of action. Biomacromolecules 4 (6) : 1457-1465.
139. Govender S, Lutchman D, Pillay V, Chetty D, Govender T. 2006. Enhancing drug incorporation into tetracycline-loaded chitosan microspheres for periodontal therapy. J Microencapsul 23 (7) : 750-761.
140. Govender S, Pillay V, Chetty DJ, Essack SY, Dangor CM, Govender T. 2005. Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres. Int J Pharm 306 (1-2) : 24-40.
141. Helander IM, Nurmiaho-Lassila EL, Ahvenainen R, Rhoades J, Roller S. 2001. Chitosan disrupts the barrier properties of the outer membrane of Gram-negative bacteria. Int J Food Microbiol 71 (2-3) : 235-244.
142. Russell-Jones GJ. 1996. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev 20 (1) : 83-97.
143. Tamai I, Tsuji A. 1996. Carrier-mediated approaches for oral drug delivery. Adv Drug Deliv Rev 20 (1) : 5-32.
144. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. 2010. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed Nanotechnol Biol Med 6 (6) : 753-759.
145. Mehnert W, Mader K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47 (2-3) : 165-196.
146. Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 50 (1) : 161-177.
147. Muller RH, Keck CM. 2004. Challenges and solutions for the delivery of biotech drugs-A review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 113 (1-3) : 151-170.
148. zur Muhlen A, Schwarz C, Mehnert W. 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism. Eur J Pharm Biopharm 45 (2) : 149-155.
149. Gokce EH, Korkmaz E, Tuncay-Tanrõverdi S, Dellera E, Sandri G, Bonferoni MC, Ozer O. 2012. A comparative evaluation of coenzyme Q10-loaded liposomes and solid lipid nanoparticles as dermal antioxidant carriers. Int J Nanomed 7: 5109.
150. Korkm E, Gokce EH, Ozer O. 2013. Development and evaluation of coenzyme Q10 loaded solid lipid nanoparticle hydrogel for enhanced dermal delivery. Acta Pharm 63 (4) : 517-529.
151. Wissing S, Muller R. 2001. A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int J Cosmetic Sci 23 (4) : 233-243.
152. Wissing SA,Muller RH. 2003. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 254 (1) : 65-68.
153. Panyam J, Labhasetwar V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55 (3) : 329-347.
154. Brewer E, Coleman J, Lowman A. 2011. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomater 2011: 1.
155. Cavalli R, Peira E, Caputo O, Gasco MR. 1999. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with cyclodextrins. Int J Pharm 182 (1) : 59-69.
156. Stancampiano A, Acquaviva R, Campisi A, Vanella L, Ventura C, Puglisi G, Pignatello R. 2006. Technological and biological characterization of idebenone-loaded solid lipid nanoparticles prepared by a modiped solvent injection technique. J Biomed Nanotech 2 (3-4) : 3-4.
157. Schwarz C, Mehnert W. 1997. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm 157 (2) : 171-179.
158. Luo Y, Chen D, Ren L, Zhao X, Qin J. 2006. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 114 (1) : 53-59.
159. Muller RH, Ruhl D, Runge SA. 1996. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 144 (1) : 115-121.
160. Almeida AJ, Runge S, Muller RH. 1997. Peptide-loaded solid lipid nanoparticles (SLN) : Inuence of production parameters. Int J Pharm 149 (2) : 255-265.
161. Goppert TM, Muller RH. 2005. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 302 (1-2) : 172-186.
162. Zhang Z, Bu H, Gao Z, Huang Y, Gao F, Li Y. 2010. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm 394 (1-2) : 147-153.
163. Scholer N, Olbrich C, Tabatt K,Muller RH, Hahn H, Liesenfeld O. 2001. Surfactant, but not the size of solid lipid nanoparticles (SLN) inuences viability and cytokine production of macrophages. Int J Pharm 221 (1-2) : 57-67.
164. Vighi E, Ruozi B, Montanari M, Battini R, Leo E. 2007. Redispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: Characterization and ability to bind the pEGFPplasmid. Eur J Pharm Biopharm 67 (2) : 320-328.
165. Kovacevic A, Savic S, Vuleta G, Muller RH, Keck CM. 2011. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC) : Effects on size, physical stability and particle matrix structure. Int J Pharm 406 (1-2) : 163-172.
166. Kalhapure RS, Akamanchi KG. 2013. A novel biocompatible bicephalous dianionic surfactant from oleic acid for solid lipid nanoparticles. Colloids Surf B 105: 215-222.
167. Mueller RH, Maeder K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 50 (1) : 161-177.
168. Pardeshi C, Rajput P, Belgamwar V, Tekade A, Patil G, Chaudhary K, Sonje A. 2012. Solid lipid based nanocarriers: An overview/Nanonosaÿci na bazi ÿcvrstih lipida: Pregled. Acta Pharm 62 (4) : 433-472.
169. Silva AC, Gonzalez-Mira E, Garcõa ML, Egea MA, Fonseca J, Silva R, Santos D, Souto EB, Ferreira D. 2011. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN) : High pressure homogenization versus ultrasound. Colloids Surf B 86 (1) : 158-165.
170. Cavalli R, Zara GP, Caputo O, Bargoni A, Fundarò A, Gasco MR. 2000. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I-A pharmacokinetic study. Pharmacol Res 42 (6) : 541-545.
171. Bargoni A, Cavalli R, Zara GP, Fundarò A, Caputo O, Gasco MR. 2001. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (sln) after duodenal administration to rats. Part II-Tissue distribution. Pharmacol Res 43 (5) : 497-502.
172. Jain D, Banerjee R. 2008. Comparison of ciprooxacin hydrochloride-loaded protein, lipid, and chitosan nanoparticles for drug delivery. J Biomed Mater Res B 86B (1) : 105-112.
173. Xie S, Zhu L, Dong Z, Wang X, Wang Y, Li X, Zhou W. 2011. Preparation, characterization and pharmacokinetics of enrooxacinloaded solid lipid nanoparticles: Inuences of fatty acids. Colloids Surf B 83 (2) : 382-387.
174. Wang XF, Zhang SL, Zhu LY, Xie SY, Dong Z, Wang Y, Zhou WZ. 2012. Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo. Vet J 191 (1) : 115-120.
175. Wang Y, Zhu L, Dong Z, Xie S, Chen X, Lu M, Wang X, Li X, Zhou W. 2012. Preparation and stability study of noroxacin-loaded solid lipid nanoparticle suspensions. Colloids Surf B 98: 105-111.
176. Gilligan PH. 1991. Microbiology of airway disease in patients with cystic pbrosis. Clin Microbiol Rev 4 (1) : 35-51.
177. Friedman AJ, Phan J, Schairer DO, Champer J, Qin M, Pirouz A, Blecher-Paz K, Oren A, Liu PT, Modlin RL. 2012. Antimicrobial and anti-inammatory activity of chitosan-Alginate nanoparticles: A targeted therapy for cutaneous pathogens. J Invest Dermatol 133 (5) : 1231-1239.
178. Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, Wood GC. 2013. Core-shell-Type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomed Nanotech Biol Med 9 (4) : 474-491.
179. Cheow WS, Hadinoto K. 2011. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B 85 (2) : 214-220.
180. Gomes JFPS, Rocha S, Pereira MdC, Peres I, Moreno S, Toca-Herrera J, Coelho MAN. 2010. Lipid/particle assemblies based on maltodextrin-gum arabic core as bio-carriers. Colloids Surf B 76 (2) : 449-455.
181. Troutier A-L, Delair T, Pichot C, Ladavière C. 2005. Physicochemical and interfacial investigation of lipid/polymer particle assemblies. Langmuir 21 (4) : 1305-1313.
182. Fang RH, Aryal S, Hu C-MJ, Zhang L. 2010. Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir 26 (22) : 16958-16962.
183. Bershteyn A, Chaparro J, Yau R, Kim M, Reinherz E, Ferreira-Moita L, Irvine DJ. 2008. Polymer-supported lipid shells, onions, and owers. Soft Matter 4 (9) : 1787-1791.
184. Cheow WS, Chang MW, Hadinoto K. 2011. The roles of lipid in anti-bioplm efpcacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surf A 389 (1-3) : 158-165.
185. Cheow WS, Hadinoto K. 2012. Lipid-polymer hybrid nanoparticles with rhamnolipid-Triggered release capabilities as anti-bioplm drug delivery vehicles. Particuology 10 (3) : 327-333.
186. Wang Y, Kho K, Cheow WS, Hadinoto K. 2012. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm 424 (1-2) : 98-106.
187. Abbaspour M, Makhmalzadeh BS, Arastoo Z, Jahangiri A, Shiralipour R. 2013. Effect of anionic polymers on drug loading and release from clindamycin phosphate solid lipid nanoparticles. Trop J Pharm Res 12 (4) : 477-482.
188. Sampathkumar SG, Yarema KJ. 2007. Dendrimers in cancer treatment and diagnosis. Nanotechnol Life Sci 7, 1-43.
189. Hawker CJ, Frechet JMJ. 1990. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc 112 (21) : 7638-7647.
190. Tomalia DA, Naylor AM, Goddard WA. 1990. Starburst dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and exibility from atoms to macroscopic matter. Angew Chem Int Ed 29 (2) : 138-175.
191. Tomalia DA, Durst HD. 1993. Genealogically directed synthesis: Starburst/cascade dendrimers and hyperbranched structures. In Supramolecular chemistry I-Directed synthesis and molecular recognition (Topics in current chemistry 165). Springer, Berlin Heidelberg, pp 193-313.
192. Voit B. 1995. Dendritic polymers: From aesthetic macromolecules to commercially interesting materials. Acta Polym 46 (2) : 87-99.
193. Ardoin N, Astruc D. 1995. Molecular trees: From syntheses towards applications. Bull Soc Chim Fr 132 (9) : 875-909.
194. Newkome G, Moorepeld C, Vogtle F. 1996. Dendritic molecules: Concepts, synthesis, perspectives.Weinheim (Germany) and New York: VCH.
195. Tomalia D, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. 1985. A new class of polymers: Starburst-dendritic macromolecules. Polym J 17 (1) : 117-132.
196. Kalhapure RS, et al., (2013) Dendrimers-From organic synthesis to pharmaceutical applications: An update. Pharm Dev Technol. http://10.3109/10837450.2013.862264.
197. Bosman AW, Janssen HM, Meijer EW. 1999. About dendrimers: Structure, physical properties, and applications. Chem Rev 99 (7) : 1665-1688.
198. Medina SH, El-Sayed MEH. 2009. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 109 (7) : 3141-3157.
199. van Heerbeek R, Kamer PCJ, van Leeuwen PWNM, Reek JNH. 2002. Dendrimers as support for recoverable catalysts and reagents. Chem Rev 102 (10) : 3717-3756.
200. Bronstein LM, Shifrina ZB. 2011. Dendrimers as encapsulating, stabilizing, or directing agents for inorganic nanoparticles. Chem Rev 111 (9) : 5301-5344.
201. Grayson SM, Frechet JMJ. 2001. Convergent dendrons and dendrimers: From synthesis to applications. Chem Rev 101 (12) : 3819-3868.
202. Bhadra D, Yadav A, Bhadra S, Jain N. 2005. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 295 (1) : 221-233.
203. Kim Y, Zeng F, Zimmerman SC. 1999. Peptide dendrimers from natural amino acids. Chem Eur J 5 (7) : 2133-2138.
204. Tuuttila T, Lipsonen J, Lahtinen M, Huuskonen J, Rissanen K. 2008. Synthesis and characterization of chiral azobenzene dye functionalized Janus dendrimers. Tetrahedron 64 (46) : 10590-10597.
205. Percec V, Wilson DA, Leowanawat P, Wilson CJ, Hughes AD, Kaucher MS, Hammer DA, Levine DH, Kim AJ, Bates FS. 2010. Selfassembly of Janus dendrimers into uniform dendrimersomes and other complex architectures. Science 328 (5981) : 1009-1014.
206. Berger A, Gebbink RJK, van Koten G. 2006. Transition metal dendrimer catalysts. In Dendrimer catalysis. Springer, Berlin Heidelberg, pp 1-38.
207. Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. 2005. Doxorubicin-PAMAM dendrimer complex attached to liposomes: Cytotoxic studies against human cancer cell lines. Int J Pharm 302 (1-2) : 29-38.
208. Devarakonda B, Hill RA, Liebenberg W, Brits M, de Villiers MM. 2005. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm 304 (1) : 193-209.
209. Hui H, Xiao-dong F, Zhong-lin C. 2005. Thermo-And pH-sensitive dendrimer derivatives with a shell of poly N,N-dimethylaminoethyl methacrylate) and study of their controlled drug release behavior. Polymer 46 (22) : 9514-9522.
210. Agarwal A, Saraf S, Asthana A, Gupta U, Gajbhiye V, Jain NK. 2008. Ligand based dendritic systems for tumor targeting. Int J Pharm 350 (1) : 3-13.
211. Kono K, Kojima C, Hayashi N, Nishisaka E, Kiura K, Watarai S, Harada A. 2008. Preparation and cytotoxic activity of poly (ethylene glycol) -modiped poly (amidoamine) dendrimers bearing adriamycin. Biomaterials 29 (11) : 1664-1675.
212. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. 2004. The use of a dendrimer-propranolol prodrug to bypass efux transporters and enhance oral bioavailability. J Control Release 95 (3) : 447-453.
213. Tang S, June SM, Howell BA, Chai M. 2006. Synthesis of salicylate dendritic prodrugs. Tetrahedron Lett 47 (44) : 7671-7675.
214. Najlah M, Freeman S, Attwood D, D'Emanuele A. 2007. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm 336 (1) : 183-190.
215. Jiang Y-H, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai C-C. 2005. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89. 6P in macaques. AIDS Res Hum Retroviruses 21 (3) : 207-213.
216. Dufès C, Uchegbu IF, Schatzlein AG. 2005. Dendrimers in gene delivery. Adv Drug Deliv Rev 57 (15) : 2177-2202.
217. Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR Jr. 2000. The use of PAMAM dendrimers in the efpcient transfer of genetic material into cells. Pharm Sci Technol Today 3 (7) : 232-245.
218. Moreno R, Jiang L, Moehle K, Zurbriggen R, Gl uck R, Robinson JA, Pluschke G. 2001. Exploiting conformationally constrained peptidomimetics and an efpcient human-compatible delivery system in synthetic vaccine design. Chem Bio Chem 2 (11) : 838-843.
219. Peng C, Zheng L, Chen Q, Shen M, Guo R, Wang H, Cao X, Zhang G, Shi X. 2012. PEGylated dendrimer-entrapped gold nanoparticles for in vivo blood pool and tumor imaging by computed tomography. Biomaterials 33 (4) : 1107-1119.
220. Chauhan AS, Diwan PV, Jain NK, Tomalia DA. 2009. Unexpected in vivo anti-inammatory activity observed for simple, surface functionalized poly (amidoamine) dendrimers. Biomacromolecules 10 (5) : 1195-1202.
221. Tulu M, Erturk AS. 2012. Dendrimers as antibacterial agents. In A search for antibacterial agents; Bobbarala V, Ed. Intech, Rijeka, Croatia, pp 89-106.
222. Castonguay A, Ladd E, van de Ven TG, Kakkar A. 2012. Dendrimers as bactericides. New J Chem 36 (2) : 199-204.
223. Rojo J, Delgado R. 2007. Dendrimers and dendritic polymers as anti-infective agents: New antimicrobial strategies for therapeutic drugs. Anti-Infect Agents Med Chem 6 (3) : 151-174.
224. Cheng Y, Qu H, Ma M, Xu Z, Xu P, Fang Y, Xu T. 2007. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: An in vitro study. Eur J Med Chem 42 (7) : 1032-1038.
225. Nguyen PM, Zacharia NS, Verploegen E, Hammond PT. 2007. Extended release antibacterial layer-by-layer plms incorporating linear-dendritic block copolymer micelles. Chem Mater 19 (23) : 5524-5530.
226. Ma M, Cheng Y, Xu Z, Xu P, Qu H, Fang Y, Xu T, Wen L. 2007. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 42 (1) : 93-98.
227. Bosnjakovic A, Mishra MK, Ren W, Kurtoglu YE, Shi T, Fan D, Kannan RM. 2011. Poly (amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inammation. Nanomed Nanotech Biol Med 7 (3) : 284-294.
228. Mishra MK, Kotta K, Hali M, Wykes S, Gerard HC, Hudson AP, Whittum-Hudson JA, Kannan RM. 2011. PAMAM dendrimerazithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomed Nanotech Biol Med 7 (6) : 935-944.
229. Winnicka K, Wroblewska M,Wieczorek P, Sacha P, Tryniszewska E. 2013. The effect of PAMAM dendrimers on the antibacterial activity of antibiotics with different water solubility. Molecules 18 (7) : 8607-8617.
230. Strydom SJ, Rose WE, Otto DP, Liebenberg W, de Villiers MM. 2013. Poly (amidoamine) dendrimer-mediated synthesis and stabilization of silver sulfonamide nanoparticles with increased antibacterial activity. Nanomed Nanotech Biol Med 9 (1) : 85-93.
231. Choi SK, Myc A, Silpe JE, Sumit M,Wong PT, McCarthy K, Desai AM, Thomas TP, Kotlyar A, Holl MM, Orr BG, Baker JR Jr. 2013. Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. ACS Nano 7 (1) : 214-228.
232. Felczak A, Zawadzka K, Wronska N, Janaszewska A, Klajnert B, Bryszewska M, Appelhans D, Voit B, Lisowska K. 2013. Enhancement of antimicrobial activity by co-Administration of poly (propylene imine) dendrimers and nadioxacin. New J Chem 37 (12) : 4156-4162.
233. Wronska N, Felczak A, Zawadzka K, Janaszewska A, Klajnert B, Bryszewska M, Lisowska K. 2014. The antibacterial effect of the coadministration of poly (propylene imine) dendrimers and ciprooxacin. New J Chem 38 (7) : 2987-2992.
234. Zhou Y-J, Zhang M-X, Hider RC, Zhou T. 2014. In vitro antimicrobial activity of hydroxypyridinone hexadentate-based dendrimeric chelators alone and in combination with noroxacin. FEMS Microbiol Lett 355 (2) : 124-130.
235. Kell AJ, Stewart G, Ryan S, Peytavi R, Boissinot M, Huletsky A, Bergeron MG, Simard B. 2008. Vancomycin-modiped nanoparticles for efpcient targeting and preconcentration of Gram-positive and Gramnegative bacteria. ACS Nano 2 (9) : 1777-1788.
236. Chung HJ, Reiner T, Budin G, Min C, Liong M, Issadore D, Lee H, Weissleder R. 2011. Ubiquitous detection of Gram-positive bacteria with bioorthogonal magnetouorescent nanoparticles. ACS Nano 5 (11) : 8834-8841.
237. Metallo SJ, Kane RS, Holmlin RE, Whitesides GM. 2003. Using bifunctional polymers presenting vancomycin and uorescein groups to direct anti-uorescein antibodies to self-Assembled monolayers presenting D-Alanine-D-Alanine groups. J Am Chem Soc 125 (15) : 4534-4540.
238. Walsh CT, Fisher SL, Park I-S, Prahalad M,Wu Z. 1996. Bacterial resistance to vancomycin: Five genes and one missing hydrogen bond tell the story. Chem Biol 3 (1) : 21-28.
239. Anton N, Vandamme TF. 2009. The universality of low-energy nano-emulsipcation. Int J Pharm 377 (1-2) : 142-147.
240. Anton N, Vandamme TF. 2011. Nano-emulsions and microemulsions: Claripcations of the critical differences. Pharm Res 28 (5) : 978-985.
241. Santos-Magalhaes N, Pontes A, Pereira V, Caetano M. 2000. Colloidal carriers for benzathine penicillin G: Nanoemulsions and nanocapsules. Int J Pharm 208 (1) : 71-80.
242. Borhade V, Pathak S, Sharma S, Patravale V. 2012. Clotrimazole nanoemulsion for malaria chemotherapy. Part I: Preformulation studies, formulation design and physicochemical evaluation. Int J Pharm 431 (1-2) : 138-148.
243. Yuan Y, Gao Y, Zhao J, Mao L. 2008. Characterization and stability evaluation of carotene nanoemulsions prepared by high pressure homogenization under various emulsifying conditions. Food Res Int 41 (1) : 61-68.
244. Tang SY, Shridharan P, Sivakumar M. 2013. Impact of process parameters in the generation of novel aspirin nanoemulsions-Comparative studies between ultrasound cavitation and microuidizer. Ultrason Sonochem 20 (1) : 485-497.
245. Ghosh V, Mukherjee A, Chandrasekaran N. 2013. Ultrasonic emulsipcation of food-grade nanoemulsion formulation and evaluation of its bactericidal activity. Ultrason Sonochem 20 (1) : 338-344.
246. Fernandez P, Andre V, Rieger J, Kuhnle A. 2004. Nano-emulsion formation by emulsion phase inversion. Colloids Surf A 251 (1) : 53-58.
247. Ahmed M, Ramadan W, Rambhu D, Shakeel F. 2008. Potential of nanoemulsions for intravenous delivery of rifampicin. Die Pharmazie 63 (11) : 806-811.
248. Lin Y-H, Chiou S-F, Lai C-H, Tsai S-C, Chou C-W, Peng S-F, He Z-S. 2012. Formulation and evaluation of water-in-oil amoxicillinloaded nanoemulsions using forHelicobacter pylori eradication. Process Biochem 47 (10) : 1469-1478.
249. Jain V, Singodia D, Gupta GK, Garg D, Keshava GBS, Shukla R, Shukla PK, Mishra PR. 2011. Ciprooxacin surf-plexes in sub-micron emulsions: A novel approach to improve payload efpciency and antimicrobial efpcacy. Int J Pharm 409 (1-2) : 237-244.
250. Liang R, Xu S, Shoemaker CF, Li Y, Zhong F, Huang Q. 2012. Physical and antimicrobial properties of peppermint oil nanoemulsions. J Agri Food Chem 60 (30) : 7548-7555.
251. Sugumar S, Ghosh V, Nirmala MJ, Mukherjee A, Chandrasekaran N. 2014. Ultrasonic emulsipcation of eucalyptus oil nanoemulsion: Antibacterial activity against Staphylococcus aureus and wound healing activity in Wistar rats. Ultrason Sonochem 21 (3) : 1044-1049.
252. Matsumura Y. 2008. Polymeric micellar delivery systems in oncology. Jpn J Clin Oncol 38 (12) : 793-802.
253. Torchilin VP. 2001. Structure and design of polymeric surfactantbased drug delivery systems. J Control Release 73 (2-3) : 137-172.
254. Prompruk K, Govender T, Zhang S, Xiong CD, Stolnik S. 2005. Synthesis of a novel PEG-block-poly (aspartic acid-stat-phenylalanine) copolymer shows potential for formation of a micellar drug carrier. Int J Pharm 297 (1-2) : 242-253.
255. Govender T, Stolnik S, Xiong C, Zhang S, Illum L, Davis SS. 2001. Drug-polyionic block copolymer interactions for micelle formation: Physicochemical characterisation. J Control Release 75 (3) : 249-258.
256. Kwon GS, Kataoka K. 1995. Block copolymer micelles as longcirculating drug vehicles. Adv Drug Deliv Rev 16 (2-3) : 295-309.
257. Kwon GS, Okano T. 1996. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 21 (2) : 107-116.
258. Khanal A, Nakashima K. 2005. Incorporation and release of cloxacillin sodium in micelles of poly (styrene-b-2-vinyl pyridine-bethylene oxide). J Control Release 108 (1) : 150-160.
259. Harada A, Kataoka K. 2006. Supramolecular assemblies of block copolymers in aqueous media as nanocontainers relevant to biological applications. Prog Polym Sci 31 (11) : 949-982.
260. Civiale C, Licciardi M, Cavallaro G, Giammona G, Mazzone MG. 2009. Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int J Pharm 378 (1-2) : 177-186.
261. Liu L, Venkatraman SS, Yang YY, Guo K, Lu J, He B, Moochhala S, Kan L. 2008. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers 90 (5) : 617-623.
262. Kenawy E-R, Worley SD, Broughton R. 2007. The chemistry and applications of antimicrobial polymers: A state-of-The-Art review. Biomacromolecules 8 (5) : 1359-1384.
263. Wang Y, Xu J, Zhang Y, Yan H, Liu K. 2011. Antimicrobial and hemolytic activities of copolymers with cationic and hydrophobic groups: A comparison of block and random copolymers. Macromol Biosci 11 (11) : 1499-1504.
264. Jang J, Kim Y. 2008. Fabrication of monodisperse silica-polymer core-shell nanoparticles with excellent antimicrobial efpcacy. Chem Commun (34) : 4016-4018.
265. Yuan W, Wei J, Lu H, Fan L, Du J. 2012. Water-dispersible and biodegradable polymer micelles with good antibacterial efpcacy. Chem Commun 48 (54) : 6857-6859.
266. Milovic NM, Wang J, Lewis K, Klibanov AM. 2005. Immobilized N-Alkylated polyethylenimine avidly kills bacteria by rupturing cell membranes with no resistance developed. Biotechnol Bioeng 90 (6) : 715-722.
267. Lenoir S, Pagnoulle C, Galleni M, Compère P, Jeröome R, Detrembleur C. 2006. Polyolepn matrixes with permanent antibacterial activity: Preparation, antibacterial activity, and action mode of the active species. Biomacromolecules 7 (8) : 2291-2296.
268. Hyung H, Fortner JD, Hughes JB, Kim J-H. 2007. Natural organic matter stabilizes carbon nanotubes in the aqueous phase. Environ Sci Technol 41 (1) : 179-184.
269. Rastogi V, Yadav P, Bhattacharya SS, Mishra AK, Verma N, Verma A, Pandit JK. 2014. Carbon nanotubes: An emerging drug carrier for targeting cancer cells. J Drug Deliv 2014: 23.
270. Li C, Thostenson ET, Chou T-W. 2008. Sensors and actuators based on carbon nanotubes and their composites: A review. Compos Sci Technol 68 (6) : 1227-1249.
271. Kang S, Pinault M, Pfefferle LD, Elimelech M. 2007. Singlewalled carbon nanotubes exhibit strong antimicrobial activity. Langmuir 23 (17) : 8670-8673.
272. Aslan S, Loebick CZ, Kang S, Elimelech M, Pfefferle LD, Van Tassel PR. 2010. Antimicrobial biomaterials based on carbon nanotubes dispersed in poly (lactic-co-glycolic acid). Nanoscale 2 (9) : 1789-1794.
273. Qi X, Poernomo G, Wang K, Chen Y, Chan-Park MB, Xu R, Chang MW. 2011. Covalent immobilization of nisin on multi-walled carbon nanotubes: Superior antimicrobial and anti-bioplm properties. Nanoscale 3 (4) : 1874-1880.
274. Qi X, Gunawan P, Xu R, Chang MW. 2012. Cefalexin-immobilized multi-walled carbon nanotubes show strong antimicrobial and antiadhesion properties. Chem Eng Sci 84: 552-556.
275. Wadhwa S, Rea C, O'Hare P, Mathur A, Roy S, Dunlop P, Byrne J, Burke G, Meenan B, McLaughlin J. 2011. Comparative in vitro cytotoxicity study of carbon nanotubes and titania nanostructures on human lung epithelial cells. J Hazard Mater 191 (1) : 56-61.
276. Casey A, Herzog E, Lyng F, Byrne H, Chambers G, Davoren M. 2008. Single walled carbon nanotubes induce indirect cytotoxicity by medium depletion in A549 lung cells. Toxicol Lett 179 (2) : 78-84.
277. Tian F, Cui D, Schwarz H, Estrada GG, Kobayashi H. 2006. Cytotoxicity of single-wall carbon nanotubes on human pbroblasts. Toxicol In Vitro 20 (7) : 1202-1212.
278. Murata K, Kaneko K, SteeleWA,Kokai F, Takahashi K, Kasuya D, Yudasaka M, Iijima S. 2001. Porosity evaluation of intrinsic intraparticle nanopores of single wall carbon nanohorn. Nano Lett 1 (4) : 197-199.
279. Murata K, Kaneko K, Kokai F, Takahashi K, Yudasaka M, Iijima S. 2000. Pore structure of single-wall carbon nanohorn aggregates. Chem Phys Lett 331 (1) : 14-20.
280. Iijima S, Yudasaka M, Yamada R, Bandow S, Suenaga K, Kokai F, Takahashi K. 1999. Nano-Aggregates of single-walled graphitic carbon nano-horns. Chem Phys Lett 309 (3-4) : 165-170.
281. Yamaguchi T, Bandow S, Iijima S. 2004. Synthesis of carbon nanohorn particles by simple pulsed arc discharge ignited between pre-heated carbon rods. Chem Phys Lett 389 (1-3) : 181-185.
282. Ajima K, Maigne A, Yudasaka M, Iijima S. 2006. Optimum holeopening condition for cisplatin incorporation in single-wall carbon nanohorns and its release. J Phys Chem B 110 (39) : 19097-19099.
283. Ajima K, Yudasaka M, Maigne A, Miyawaki J, Iijima S. 2006. Effect of functional groups at hole edges on cisplatin release from inside single-wall carbon nanohorns. J Phys Chem B 110 (11) : 5773-5778.
284. Xu J, Yudasaka M, Kouraba S, Sekido M, Yamamoto Y, Iijima S. 2008. Single wall carbon nanohorn as a drug carrier for controlled release. Chem Phys Lett 461 (4-6) : 189-192.
285. Hormozi-Nezhad MR, Jalali-Heravi M, Robatjazi H, Ebrahimi-Najafabadi H. 2012. Controlling aspect ratio of colloidal silver nanorods using response surface methodology. Colloids Surf A 393: 46-52.
286. Pei LZ, Zhao HS, Tan W, Yu HY, Chen YW, Zhang Q-F. 2009. Single crystalline ZnO nanorods grown by a simple hydrothermal process. Mater Charact 60 (9) : 1063-1067.
287. Ding X, Zeng D, Xie C. 2010. Controlled growth of SnO2 nanorods clusters via Zn doping and its inuence on gas-sensing properties. Sensor Actuat B-Chem 149 (2) : 336-344.
288. Shamsipur M, Pourmortazavi SM, Hajimirsadeghi SS, Roushani M. 2013. Applying Taguchi robust design to the optimization of synthesis of barium carbonate nanorods via direct precipitation. Colloids Surf A 423: 35-41.
289. Huang H, Liu X, Zeng Y, Yu X, Liao B, Yi P, Chu PK. 2009. Optical and biological sensing capabilities of Au2S/AuAgS coated gold nanorods. Biomaterials 30 (29) : 5622-5630.
290. Alkilany AM, Thompson LB, Boulos SP, Sisco PN, Murphy CJ. 2012. Gold nanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv Drug Deliv Rev 64 (2) : 190-199.
291. Pissuwan D, Niidome T, Cortie MB. 2011. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 149 (1) : 65-71.
292. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, Katayama Y, Niidome Y. 2006. PEG-modiped gold nanorods with a stealth character for in vivo applications. J Control Release 114 (3) : 343-347.
293. Ahymah Joshy MI, Elayaraja K, Suganthi RV, Chandra Veerla S, Kalkura SN. 2011. In vitro sustained release of amoxicillin from lanthanum hydroxyapatite nano rods. Curr Appl Phys 11 (4) : 1100-1106.
294. Trikeriotis M, Ghanotakis DF. 2007. Intercalation of hydrophilic and hydrophobic antibiotics in layered double hydroxides. Int J Pharm 332 (1-2) : 176-184.
295. Cavani F, Triprò F, Vaccari A. 1991. Hydrotalcite-Type anionic clays: Preparation, properties and applications. Catal Today 11 (2) : 173-301.
296. Vittoria V, Marenzi G, Bolognese A ea. 2005. Sistema di rilascio controllato di sostanze farmacologicamente attive, processo di preparazione e impieghi in campo medico. Ns Rif.: 6698PTIT. DOM: RM2005A000393.
297. Meyn M, Beneke K, Lagaly G. 1990. Anion-exchange reactions of layered double hydroxides. Inorg Chem 29 (26) : 5201-5207.
298. Tammaro L, Costantino U, Bolognese A, Sammartino G, Marenzi G, Calignano A, Tetè S, Mastrangelo F, Califano L, Vittoria V. 2007. Nanohybrids for controlled antibiotic release in topical applications. Int J Antimicrob Agents 29 (4) : 417-423.
299. Khan AI, Lei L, Norquist AJ, O'Hare D. 2001. Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide. Chem Commun (22) : 2342-2343.
300. Valarezo E, Tammaro L, Gonzalez S, Malagon O, Vittoria V. 2013. Fabrication and sustained release properties of poly (g-caprolactone) electrospun pbers loaded with layered double hydroxide nanoparticles intercalated with amoxicillin. Appl Clay Sci 72 (0) : 104-109.
301. Das B, Chattopadhyay P, Upadhyay A, Gupta K, Mandal M, Karak N. 2014. Biophysico-chemical interfacial attributes of Fe3O4 decorated MWCNTnanohybrid/bio-based hyperbranched polyurethane nanocomposite: An antibacterial wound healing material with controlled drug release potential. New J Chem 38: 4300-4311.
302. Reddy TT, Hadano M, Takahara A. 2006. Controlled release of model drug from biodegradable segmented polyurethane ureas: Morphological and structural features. Macromol Symp 242 (1) : 241-249.
303. Ko FK, Wan Y. 2014. Introduction to nanopber materials. Cambridge University Press, UK.
304. Khil MS, Cha DI, Kim HY, Kim IS, Bhattarai N. 2003. Electrospun nanopbrous polyurethane membrane as wound dressing. J Biomed Mater Res B 67 (2) : 675-679.
305. Chen DW, Hsu Y-H, Liao J-Y, Liu S-J, Chen J-K, Ueng SW-N. 2012. Sustainable release of vancomycin, gentamicin and lidocaine from novel electrospun sandwich-structured PLGA/collagen nanopbrous membranes. Int J Pharm 430 (1-2) : 335-341.
306. Kataria K, Gupta A, Rath G, Mathur R, Dhakate S. 2014. In vivo wound healing performance of drug loaded electrospun composite nanopbers transdermal patch. Int J Pharm 469 (1) : 102-110.
307. Zhang LF, Yang DJ, Chen HC, Sun R, Xu L, Xiong ZC, Govender T, Xiong CD. 2008. An ionically crosslinked hydrogel containing vancomycin coating on a porous scaffold for drug delivery and cell culture. Int J Pharm 353 (1-2) : 74-87.
308. Li WJ, Laurencin CT, Caterson EJ, Tuan RS, Ko FK. 2002. Electrospun nanopbrous structure: A novel scaffold for tissue engineering. J Biomed Mater Res 60 (4) : 613-621.
309. Kim K, Luu YK, Chang C, Fang D, Hsiao BS, Chu B, Hadjiargyrou M. 2004. Incorporation and controlled release of a hydrophilic antibiotic using poly (lactide-co-glycolide) -based electrospun nanopbrous scaffolds. J Control Release 98 (1) : 47-56.
310. Smith LA, Liu X, Ma PX. 2008. Tissue engineering with nanopbrous scaffolds. Soft Matter 4 (11) : 2144-2149.
311. Feng K, Sun H, Bradley MA, Dupler EJ, Giannobile WV, Ma PX. 2010. Novel antibacterial nanopbrous PLLA scaffolds. J Control Release 146 (3) : 363-369.
312. Shi X, Wang Y, Ren L, Huang W, Wang D-A. 2009. A protein/antibiotic releasing poly (lactic-co-glycolic acid)/lecithin scaffold for bone repair applications. Int J Pharm 373 (1-2) : 85-92.
313. Thakur RA, Florek CA, Kohn J, Michniak BB. 2008. Electrospun nanopbrous polymeric scaffold with targeted drug release proples for potential application as wound dressing. Int J Pharm 364 (1) : 87-93.
314. Jiang C, Markutsya S, Pikus Y, Tsukruk VV. 2004. Freely suspended nanocomposite membranes as highly sensitive sensors. Nat Mater 3 (10) : 721-728.
315. Jiang C, Tsukruk VV. 2006. Freestanding nanostructures via layer-by-layer assembly. Adv Mater 18 (7) : 829-840.
316. Ono SS, Decher G. 2006. Preparation of ultrathin self-standing polyelectrolyte multilayer membranes at physiological conditions using pH-responsive plm segments as sacripcial layers. Nano Lett 6 (4) : 592-598.
317. Vendamme R, Onoue S-Y, Nakao A, Kunitake T. 2006. Robust free-standing nanomembranes of organic/inorganic interpenetrating networks. Nat Mater 5 (6) : 494-501.
318. Endo H, Kado Y, Mitsuishi M, Miyashita T. 2006. Fabrication of free-standing hybrid nanosheets organized with polymer Langmuir-Blodgett plms and gold nanoparticles. Macromolecules 39 (16) : 5559-5563.
319. Fujie T, Saito A, Kinoshita M, Miyazaki H, Ohtsubo S, Saitoh D, Takeoka S. 2010. Dual therapeutic action of antibiotic-loaded nanosheets for the treatment of gastrointestinal tissue defects. Biomaterials 31 (24) : 6269-6278.
320. Saito A, Miyazaki H, Fujie T, Ohtsubo S, Kinoshita M, Saitoh D, Takeoka S. 2012. Therapeutic efpcacy of an antibiotic-loaded nanosheet in a murine burn-wound infection model. Acta Biomater 8 (8) : 2932-2940.
321. Cheow WS, Hadinoto K. 2012. Self-Assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility. J Colloid Interface Sci 367 (1) : 518-526.
322. Cheow WS, Hadinoto K. 2012. Green preparation of antibiotic nanoparticle complex as potential anti-bioplm therapeutics via selfassembly amphiphile-polyelectrolyte complexation with dextran sulfate. Colloids Surf B 92: 55-63.